TY - JOUR
T1 - Inherited cardiac arrhythmias
AU - Schwartz, Peter J.
AU - Ackerman, Michael J.
AU - Antzelevitch, Charles
AU - Bezzina, Connie R.
AU - Borggrefe, Martin
AU - Cuneo, Bettina F.
AU - Wilde, Arthur A.M.
N1 - Funding Information:
Foundation for Cardiovascular Research grant 18CVD05 “Towards Precision Medicine with Human iPSCs for Cardiac Channelopathies” and of ESCAPE-NET project (European Union’s Framework Horizon 2020 programme under grant agreement no. 733381). M.B. acknowledges support from the German Center for Cardiovascular Research (DZHK) and Hector Foundation. M.J.A. acknowledges support from the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.
Funding Information:
The authors thank P. De Tomasi (Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy) for an extraordinary editorial support. C.A. acknowledges support from NHLBI (HL47678, HL138103 and HL152201), the W.W. Smith Charitable Trust and the Martha and Wistar Morris Fund; C.R.B., P.J.S. and A.A.M.W. acknowledge the support of ERN GUARD-Heart; C.R.B. and A.A.M.W. acknowledge the support of the Netherlands Heart Foundation (CVON Predict2 project) and Leducq Foundation for Cardiovascular Research grant 17CVD02 “The sodium channel as a therapeutic target for prevention of lethal cardiac arrhythmias”; P.J.S. acknowledges the support of Leducq
Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The main inherited cardiac arrhythmias are long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome. These rare diseases are often the underlying cause of sudden cardiac death in young individuals and result from mutations in several genes encoding ion channels or proteins involved in their regulation. The genetic defects lead to alterations in the ionic currents that determine the morphology and duration of the cardiac action potential, and individuals with these disorders often present with syncope or a life-threatening arrhythmic episode. The diagnosis is based on clinical presentation and history, the characteristics of the electrocardiographic recording at rest and during exercise and genetic analyses. Management relies on pharmacological therapy, mostly β-adrenergic receptor blockers (specifically, propranolol and nadolol) and sodium and transient outward current blockers (such as quinidine), or surgical interventions, including left cardiac sympathetic denervation and implantation of a cardioverter–defibrillator. All these arrhythmias are potentially life-threatening and have substantial negative effects on the quality of life of patients. Future research should focus on the identification of genes associated with the diseases and other risk factors, improved risk stratification and, in particular for Brugada syndrome, effective therapies.
AB - The main inherited cardiac arrhythmias are long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome. These rare diseases are often the underlying cause of sudden cardiac death in young individuals and result from mutations in several genes encoding ion channels or proteins involved in their regulation. The genetic defects lead to alterations in the ionic currents that determine the morphology and duration of the cardiac action potential, and individuals with these disorders often present with syncope or a life-threatening arrhythmic episode. The diagnosis is based on clinical presentation and history, the characteristics of the electrocardiographic recording at rest and during exercise and genetic analyses. Management relies on pharmacological therapy, mostly β-adrenergic receptor blockers (specifically, propranolol and nadolol) and sodium and transient outward current blockers (such as quinidine), or surgical interventions, including left cardiac sympathetic denervation and implantation of a cardioverter–defibrillator. All these arrhythmias are potentially life-threatening and have substantial negative effects on the quality of life of patients. Future research should focus on the identification of genes associated with the diseases and other risk factors, improved risk stratification and, in particular for Brugada syndrome, effective therapies.
UR - http://www.scopus.com/inward/record.url?scp=85088091668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088091668&partnerID=8YFLogxK
U2 - 10.1038/s41572-020-0188-7
DO - 10.1038/s41572-020-0188-7
M3 - Article
C2 - 32678103
AN - SCOPUS:85088091668
SN - 2056-676X
VL - 6
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 58
ER -